8-K: Orchestra BioMed Receives FDA Breakthrough Device Designation and IDE Approval for Hypertension and Artery Disease Therapies

Orchestra BioMed announces FDA Breakthrough Device Designation for its AVIM therapy for hypertension and IDE approval for an updated Virtue Trial design for artery disease.

Summary

• Orchestra BioMed received Breakthrough Device Designation (BDD) from the FDA for its Atrioventricular Interval Modulation (AVIM) therapy to treat hypertension in patients indicated for a pacemaker.
• The BDD applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk.
• The company also received FDA approval for an Investigational Device Exemption (IDE) amendment to initiate an updated design of the Virtue Trial for its Virtue Sirolimus Infusion Balloon (Virtue SAB) to treat Coronary In-Stent Restenosis (ISR).
• The Virtue Trial will randomize 740 patients across up to 75 centers in the United States, comparing Virtue SAB to the Boston Scientific AGENT paclitaxel-coated balloon.
• The company is targeting initiation of the Virtue Trial during the second half of 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the FDA's Breakthrough Device Designation and IDE approval, indicating progress in the development of Orchestra BioMed's therapies. The management's comments and the potential market size contribute to the positive outlook.

Positives

• The Breakthrough Device Designation for AVIM therapy may expedite FDA reviews and streamline reimbursement pathways.
• The IDE approval for the Virtue Trial allows Orchestra BioMed to advance its Virtue SAB towards potential regulatory approval in the U.S.
• Virtue SAB has the potential to overcome limitations of drug-coated balloons (DCBs) by delivering a large liquid dose of an extended-release formulation of sirolimus.
• The head-to-head trial design for Virtue SAB against a paclitaxel-coated balloon offers a direct path to regulatory approval and an opportunity to demonstrate the technology's advantages.
• Virtue SAB has been previously granted FDA Breakthrough Device Designation for the treatment of coronary ISR as well as for coronary small vessel disease and peripheral artery disease below-the-knee.

Risks

• The company operates in a very competitive and rapidly changing environment.
• Regulatory approval of the company's product candidates is subject to risks and uncertainties.
• The timing of achieving expected regulatory and business milestones is uncertain.
• The impact of competitive products and product candidates poses a risk.

Future Outlook

The company is targeting initiation of the Virtue Trial during the second half of 2025 and believes there is a multibillion-dollar U.S. market for coronary drug delivery balloons.

Management Comments

• David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, commented on the potential of AVIM therapy to offer a differentiated solution for hypertension management.
• David Hochman stated that the company made a strategic decision to pursue a head-to-head trial with the commercially available AGENT paclitaxel-coated balloon, underscoring their confidence in Virtue SAB.
• Robert C. Kowal, M.D., Ph.D., Vice President and General Manager of Cardiac Pacing Therapies within the Medtronic Cardiac Rhythm Management operating unit, stated that Medtronic is committed to collaborating with Orchestra BioMed to advance AVIM therapy through the BACKBEAT global pivotal study.
• Dean J. Kereiakes, M.D., FACC, MSCAI, stated that Virtue SAB has the potential to be one of the most compelling technologies in interventional cardiology.
• Allen Jeremias, MD, MSc, commented that he anticipates continued momentum for drug-coated balloons and is eager to see how Virtue SAB performs in a head-to-head trial against a paclitaxel-coated balloon.

Industry Context

The announcements highlight the ongoing innovation in cardiovascular therapies, with a focus on addressing unmet needs in hypertension and artery disease. The use of Breakthrough Device Designations and IDE approvals reflects the FDA's efforts to expedite the development and review of innovative medical technologies.

Comparison to Industry Standards

• The Virtue Trial compares Orchestra BioMed's Virtue SAB to Boston Scientific's AGENT paclitaxel-coated balloon, which is currently the only drug-coated balloon (DCB) FDA-approved for a coronary indication.
• The company believes that Virtue SAB has the potential to achieve pharmacokinetics that match or even exceed those of proven limus-eluting stents.
• The company references a meta-analysis showing that limus-eluting stents have significantly better clinical performance than paclitaxel-eluting stents in terms of target lesion revascularization and major adverse cardiac events.

Stakeholder Impact

• Shareholders may benefit from the potential for increased value due to the regulatory milestones achieved.
• Patients may benefit from access to new and potentially more effective therapies for hypertension and artery disease.
• The company's partnerships with Medtronic and Terumo may strengthen its position in the market.

Next Steps

• Initiate the Virtue Trial in the second half of 2025.
• Continue enrolling patients in the BACKBEAT global pivotal study for AVIM therapy.
• Work closely with the FDA and Medtronic to maximize the impact of AVIM therapy.
• Pursue regulatory approval for Virtue SAB in the U.S.

Key Dates

Keywords

Virtue SAB, AVIM therapy, Breakthrough Device Designation, IDE amendment, Hypertension, Coronary In-Stent Restenosis, FDA, Orchestra BioMed, Sirolimus, Paclitaxel